This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sorbent Therapy of the Cutaneous Porphyrias (EPP)

This study has been completed.
Information provided by (Responsible Party):
Peter Tishler, Brigham and Women's Hospital Identifier:
First received: August 23, 2011
Last updated: March 14, 2017
Last verified: March 2017
The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).

Condition Intervention Phase
Erythropoietic Protoporphyria Drug: Colestipol Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sorbent Therapy of the Cutaneous Porphyrias

Resource links provided by NLM:

Further study details as provided by Peter Tishler, Brigham and Women's Hospital:

Primary Outcome Measures:
  • Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance [ Time Frame: At 60 days of treatment ]
    Minutes of sun tolerance

  • Protoporphyrin Concentration in Blood [ Time Frame: Samples collected while on treatment (range 93-208 treatment days) ]
    1. erythrocyte protoporphyrin concentration, ug/dl
    2. plasma protoporphyrin concentration, ug/dl

Enrollment: 4
Study Start Date: May 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: colestipol treatment
2 grams morning and bedtime for 180 days
Drug: Colestipol
2 grams morning and bedtime for 90 days.

Detailed Description:
Four adults with proven EPP volunteered as subjects for this study. First period: Subjects received 1 gm colestipol twice daily for ~45 days, then 2 gm twice daily for ~45 days. Labs included CBC; liver chemistries including cholesterol; serum iron, TIBC and ferritin; erythrocyte and plasma protoporphyrin concentrations; and completion of sun exposure questionnaire focused on cutaneous manifestations every 2-4 weeks. Second period: Subjects received colestipol tablets, 2 grams twice daily, completing the sun exposure questionnaire and protoporphyrin determinations ~monthly for 5-6 months.

Ages Eligible for Study:   22 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult over age 21
  • healthy

Exclusion Criteria:

  • Intercurrent illness
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01422915

United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
  More Information

Responsible Party: Peter Tishler, physician, Brigham and Women's Hospital Identifier: NCT01422915     History of Changes
Other Study ID Numbers: 2010P002253
Study First Received: August 23, 2011
Results First Received: August 20, 2013
Last Updated: March 14, 2017

Keywords provided by Peter Tishler, Brigham and Women's Hospital:
Cutaneous porphyria
over age 21
without intercurrent illness
not pregnant
willing to participate

Additional relevant MeSH terms:
Porphyria, Erythropoietic
Porphyrias, Hepatic
Protoporphyria, Erythropoietic
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Liver Diseases
Digestive System Diseases
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Sequestering Agents processed this record on September 20, 2017